Mecillinam: Old Molecule, New Option
14 December 2017
29 April 2018
23 June 2018 (eFirst)
Background Mecillinam is a β-lactam antibiotic that is increasingly being used for the treatment of uncomplicated urinary tract infections. Nevertheless, the international guidelines still recommend nitrofurantoin, fosfomycin trometamol, and pivmecillinam as first-line agents in the treatment of such infections.
Aim The objective of this study was to determine the in vitro efficacy of mecillinam against Escherichia coli and Klebsiella pneumoniae strains isolated from children with urinary tract infections.
Materials Methods We investigated E. coli and K. pneumoniae isolates, obtained within the period from January 2016 to October 2017, from urine samples of patients aged 0 to 16 years. Antibiotics susceptibility testing was conducted through the disk diffusion method based on the guidelines provided by EUCAST (European Committee on Antimicrobial Susceptibility Testing). Extended-spectrum β-lactamase (ESBL)-positivity was detected by the double-disk synergy test. Isolates with mecillinam inhibition-zone diameter breakpoints lower than < 15 mm were considered to be resistant according to EUCAST criteria.
Results A total of 450 isolates were assessed in the study, 135 of which were ESBL-producing E.coli, 230 were non-ESBL-producing E. coli, 35 were ESBL-producing K. pneumoniae, and 50 were non-ESBL-producing K. pneumoniae isolates. Mecillinam susceptibility was observed in most of the non-ESBL-producing and ESBL-producing E. coli isolates (230/230, 100% and 115/135, 85.1%, respectively). The rates of susceptibility of the non-ESBL-producing and ESBL-producing K. pneumoniae isolates were 37/50 (74%) and 24/35 (68.6%), respectively.
Conclusion The in vitro susceptibility results obtained support the usage of mecillinam as a first-line agent. The high susceptibility of non-ESBL-producing E. coli and K. pneumoniae isolates established in vitro brings the hope that this antibiotic could soon be used in clinical practice in Turkey.
- 1 Kahlmeter G, Åhman J, Matuschek E. Antimicrobial resistance of Escherichia coli causing uncomplicated urinary tract infections: a European update for 2014 and comparison with 2000 and 2008. Infect Dis Ther 2015; 4 (04) 417-423
- 2 Theuretzbacher U, Van Bambeke F, Cantón R. , et al. Reviving old antibiotics. J Antimicrob Chemother 2015; 70 (08) 2177-2181
- 3 Cassir N, Rolain JM, Brouqui P. A new strategy to fight antimicrobial resistance: the revival of old antibiotics. Front Microbiol 2014; 5 (05) 551
- 4 Tybring L. Mecillinam (FL 1060), a 6 beta-amidinopenicillanic acid derivative: in vitro evaluation. Antimicrob Agents Chemother 1975; 8 (03) 266-270
- 5 Zhanel GG, Karlowsky JA, Schwartz B, Jensen SB, Hoban DJ. Mecillinam activity compared to ampicillin, trimethoprim/sulfamethoxazole, ciprofloxacin and nitrofurantoin against urinary tract isolates of gram-negative bacilli. Chemotherapy 1998; 44 (06) 391-396
- 6 Dewar S, Reed LC, Koerner RJ. Emerging clinical role of pivmecillinam in the treatment of urinary tract infection in the context of multidrug-resistant bacteria. J Antimicrob Chemother 2014; 69 (02) 303-308
- 7 EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance. Version 2.0, July 2017 Available at: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Resistance_mechanisms/EUCAST_detection_of_resistance_mechanisms_170711.pdf . Accessed November 23, 2017
- 8 EUCAST. Clinical Breakpoints. Available at: http://www.eucast.org/clinical_breakpoints . Accessed November 23, 2017
- 9 Wootton M, Walsh TR, Macfarlane L, Howe RA. Activity of mecillinam against Escherichia coli resistant to third-generation cephalosporins. J Antimicrob Chemother 2010; 65 (01) 79-81
- 10 Monsen TJ, Holm SE, Ferry BM, Ferry SA. Mecillinam resistance and outcome of pivmecillinam treatment in uncomplicated lower urinary tract infection in women. APMIS 2014; 122 (04) 317-323
- 11 Giske CG. Contemporary resistance trends and mechanisms for the old antibiotics colistin, temocillin, fosfomycin, mecillinam and nitrofurantoin. Clin Microbiol Infect 2015; 21 (10) 899-905
- 12 Sougakoff W, Jarlier V. Comparative potency of mecillinam and other beta-lactam antibiotics against Escherichia coli strains producing different beta-lactamases. J Antimicrob Chemother 2000; 46 (01) 9-14
- 13 Kresken M, Körber-Irrgang B, Naber KG. In-vitro activity of mecillinam against urine isolates of Escherichia coli from outpatient departments in Germany [Article in German]. Aktuelle Urol 2017; 48 (03) 243-247
- 14 Kranz J, Schmidt S, Lebert C. , et al. Epidemiology, diagnostics, therapy, prevention and management of uncomplicated bacterial outpatient acquired urinary tract infections in adult patients: update 2017 of the interdisciplinary AWMF S3 guideline [Article in German]. Urologe A 2017; 56 (06) 746-758
- 15 Bader MS, Loeb M, Brooks AA. An update on the management of urinary tract infections in the era of antimicrobial resistance. Postgrad Med 2017; 129 (02) 242-258
- 16 Lindbäck H, Lindbäck J, Melhus Å. Inadequate adherence to Swedish guidelines for uncomplicated lower urinary tract infections among adults in general practice. APMIS 2017; 125 (09) 816-821
- 17 O'Kelly F, Kavanagh S, Manecksha R, Thornhill J, Fennell JP. Characteristics of gram-negative urinary tract infections caused by extended spectrum beta lactamases: pivmecillinam as a treatment option within South Dublin, Ireland. BMC Infect Dis 2016; 16 (01) 620
- 18 Baines SD, O'Connor R, Huscroft G, Saxton K, Freeman J, Wilcox MH. Mecillinam: a low-risk antimicrobial agent for induction of Clostridium difficile infection in an in vitro human gut model. J Antimicrob Chemother 2009; 63 (04) 838-839
- 19 Sullivan A, Fianu-Jonasson A, Landgren BM, Nord CE. Ecological effects of perorally administered pivmecillinam on the normal vaginal microflora. Antimicrob Agents Chemother 2005; 49 (01) 170-175
- 20 Fournier D, Chirouze C, Leroy J. , et al. Alternatives to carbapenems in ESBL-producing Escherichia coli infections. Med Mal Infect 2013; 43 (02) 62-66
- 21 Zykov IN, Sundsfjord A, Småbrekke L, Samuelsen Ø. The antimicrobial activity of mecillinam, nitrofurantoin, temocillin and fosfomycin and comparative analysis of resistance patterns in a nationwide collection of ESBL-producing Escherichia coli in Norway 2010-2011. Infect Dis (Lond) 2016; 48 (02) 99-107
- 22 Naber KG, Schito G, Botto H, Palou J, Mazzei T. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. Eur Urol 2008; 54 (05) 1164-1175
- 23 Schito GC, Naber KG, Botto H. , et al. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents 2009; 34 (05) 407-413
- 24 Salomonsson P, von Linstow ML, Knudsen JD. , et al. Best oral empirical treatment for pyelonephritis in children: do we need to differentiate between age and gender?. Infect Dis (Lond) 2016; 48 (10) 721-725
- 25 Titelman E, Iversen A, Kalin M, Giske CG. Efficacy of pivmecillinam for treatment of lower urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae . Microb Drug Resist 2012; 18 (02) 189-192
- 26 Pinart M, Kranz J, Jensen K. , et al. Optimal dosage and duration of pivmecillinam treatment for uncomplicated lower urinary tract infections: a systematic review and meta-analysis. Int J Infect Dis 2017; 58: 96-109
- 27 Thulin E, Thulin M, Andersson DI. Reversion of high-level mecillinam resistance to susceptibility in Escherichia coli during growth in urine. EBioMedicine 2017; 23: 111-118
- 28 Auer S, Wojna A, Hell M. Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli . Antimicrob Agents Chemother 2010; 54 (09) 4006-4008
- 29 Duployez C, Loiez C, Cattoen C, Descamps D, Wallet F, Vachée A. ; Microbiologist Network from Nord-Pas-de-Calais. In vitro susceptibility to mecillinam of Escherichia coli strains isolated from the urine of pregnant women. Med Mal Infect 2016; 46 (08) 436-441
- 30 Søraas A, Sundsfjord A, Jørgensen SB, Liestøl K, Jenum PA. High rate of per oral mecillinam treatment failure in community-acquired urinary tract infections caused by ESBL-producing Escherichia coli. PLoS One 2014; 9 (01) e85889
- 31 Lampri N, Galani I, Poulakou G. , et al. Mecillinam/clavulanate combination: a possible option for the treatment of community-acquired uncomplicated urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli . J Antimicrob Chemother 2012; 67 (10) 2424-2428
- 32 Christensen B. Which antibiotics are appropriate for treating bacteriuria in pregnancy?. J Antimicrob Chemother 2000; 46 (01) 29-34